Shijiazhuang Yiling Pharmaceutical

What Shijiazhuang Yiling Pharmaceutical does

Shijiazhuang Yiling Pharmaceutical Co., Ltd. (深圳交易所: 002603), founded in 1992 by academician Wu Yiling in Shijiazhuang, Hebei Province, is a national key high-tech pharmaceutical enterprise specializing in innovative Traditional Chinese Medicines (TCM), generic chemical drugs, health products, and TCM formula granules. The company is built on the proprietary Luo Bing (络病, Collateral Disease) theory system, a unique TCM academic framework that guides drug discovery across cardiovascular, respiratory, metabolic, and oncology indications. Core products include Tongxinluo Capsule, Shensong Yangxin Capsule, Qili Qiangxin Capsule, Lianhua Qingwen Capsule/Granule, and Jinlida — supported by 40+ international-standard RCTs published in top-tier journals (JAMA, Nature Medicine, European Heart Journal, JAMA Internal Medicine). The company holds 800+ patents, has received 6 national science and technology awards (including a 2019 First Prize), and operates 5 production bases in Hebei and Beijing with 60+ GAP-certified herb cultivation bases across 20+ provinces.

The company operates a proprietary "Theory-Clinical-New Drug-Industry-Education" five-in-one business model, recognized by the Ministry of Science and Technology as a national benchmark for TCM industrialization. Revenue is generated primarily through hospital and retail pharmacy distribution under China's National Medical Insurance system (12 of 17 innovative TCM products are insured, with 5 on the Essential Drug List), supplemented by a direct-to-consumer e-commerce storefront (yilingshop.com) and international exports to 50+ countries. Key customer segments are end patients with cardiovascular diseases, respiratory infections, and metabolic disorders, served through prescription channels. The company is family-controlled, with the Wu family (founder Wu Yiling, chairman Wu Xiangjun, Wu Rui) collectively holding approximately 54.68% as concert parties. A wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical, has begun expanding into patented chemical drugs, with multiple new chemical drug approvals in 2026 signaling a strategic pivot beyond pure TCM.

Name

Shijiazhuang Yiling Pharmaceutical

Legal name

石家庄以岭药业股份有限公司

Website

https://yiling.cn

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Shijiazhuang Yiling Pharmaceutical is a publicly listed Chinese TCM company developing innovative proprietary medicines — primarily cardiovascular, respiratory, and metabolic drugs — based on its proprietary Luo Bing theory, distributed through hospitals, pharmacies, and exports to 50+ countries.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine / Chinese Patent Medicine Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Generic Hospital & Institutional Products (HLAIABAL), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Traditional Chinese medicine
• Cardiovascular TCM drugs
• Respiratory antiviral medicines
• Pharmaceutical manufacturing
• TCM formula granules

Headquarters

HQ city

Shijiazhuang

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Proprietary TCM Products (创新中药): Sales of proprietary TCM medicines including Tongxinluo Capsule, Shensong Yangxin Capsule, Qili Qiangxin Capsule, and Lianhua Qingwen Capsule/Granule — the core revenue drivers. Products are sold through hospitals, pharmacies, and online channels domestically, and exported to over 50 countries. 12 products are covered by China's national medical insurance (医保) and 5 are on the national essential drug list (基本药物目录).
2. Generic Chemical Drugs (化药系列): Manufacturing and sale of generic chemical pharmaceutical products including antibiotics (e.g., 阿奇霉素片, 克拉霉素片), cardiovascular drugs (e.g., 酒石酸美托洛尔片, 厄贝沙坦分散片), diabetes medications (盐酸二甲双胍片, 格列喹酮片), and others. Domestic and international sales including FDA-approved products.
3. Health Products and Consumer Wellness (健康产品): OTC and consumer health products including nutritional supplements (e.g., Lingzhi spore oil soft capsules, 酸枣仁油软胶囊), functional beverages (津力旺, 怡梦), and Lianhua-branded personal care products (连花清咽抑菌喷剂, 连花爆珠口罩). Sold via the company's e-commerce platform yilingshop.com and retail channels.
4. TCM Formula Granules (配方颗粒): Standardized TCM formula granules for prescription compounding, sold to hospitals and TCM clinics. Produced using GAP-certified medicinal herbs with full quality traceability from source to patient.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Shijiazhuang Yiling Pharmaceutical researches, develops, manufactures, and sells innovative Traditional Chinese Medicine (TCM) products based on its proprietary Luo Bing (络病) theory, with flagship prescription products including Tongxinluo Capsule (cardiovascular), Shensong Yangxin Capsule (arrhythmia), Qili Qiangxin Capsule (chronic heart failure), and Lianhua Qingwen Capsule/Granule (respiratory infections). The company also manufactures generic chemical drugs, standardized TCM formula granules, and consumer health supplements, distributing through hospitals, pharmacies, its own e-commerce platform, and exports to over 50 countries.

Product overview

Shijiazhuang Yiling Pharmaceutical is a national key high-tech enterprise specializing in innovative traditional Chinese medicines, generic chemical drugs, health products, and TCM formula granules. The company operates a unique '五位一体' (Five-in-One) model combining theory, clinical practice, new drug development, industry, and education. Core products include cardiovascular TCM medicines (通心络胶囊, 参松养心胶囊, 芪苈强心胶囊), respiratory medicines (连花清瘟胶囊), and a broad portfolio of generic chemical drugs, formula granules, and health supplements. The company has 17 patented innovative TCM drugs covering 8 major clinical disease systems, with products sold in over 50 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• 以岭健康 (Yiling Health): Health management platform and health product division offering wellness products, dietary supplements, and health management services.
• 晚必安 (Wanbian)

Products and services

• Tongxinluo Capsule (通心络胶囊) Patented traditional Chinese medicine for treating coronary heart disease and angina pectoris, derived from Luo Bing theory. Regulates lipids, reduces inflammation, anti-coagulates, protects vascular endothelium, and stabilizes plaques. Used by over 100 million cumulative patients and prescribed in 50,000+ hospitals across China.
• Shensong Yangxin Capsule (参松养心胶囊) Traditional Chinese medicine for treating ventricular premature beats, paroxysmal atrial fibrillation, and bradyarrhythmias. Has multi-ion channel and non-ion channel integrated regulatory effects, validated by evidence-based clinical trials including the SS-AFRF study published in European Heart Journal (reduced AF recurrence by 40.4% post-ablation).
• Qili Qiangxin Capsule (芪苈强心胶囊) Patented TCM for chronic heart failure treatment, developed using Luo Bing theory. Benefits qi, activates yang, promotes blood circulation, and has diuretic effects. QUEST trial published in Nature Medicine demonstrated 22% reduction in MACE in HFrEF patients, 17% reduction in cardiovascular death, and 24% reduction in heart failure rehospitalization.
• Lianhua Qingwen Capsule/Granule (连花清瘟胶囊/颗粒) Patented traditional Chinese medicine developed under Luo Bing theory for treating colds and influenza. Broad-spectrum antiviral; achieved viral nucleic acid conversion time comparable to oseltamivir (Tamiflu) in H1N1 patients. Reduced severe COVID-19 progression rate by 50%. Recommended in 27+ national treatment protocols. Registered in 30+ countries.
• TCM Formula Granules (配方颗粒) Standardized traditional Chinese medicine formula granules for prescription compounding, made from GAP-certified medicinal materials with full-chain traceability from herb cultivation to patient. Sold to TCM hospitals, integrated TCM-Western medicine hospitals, and TCM clinics.
• Generic Chemical Pharmaceutical Series (化学药品系列) Generic chemical drug portfolio including antibiotics (e.g., Azithromycin, Clarithromycin tablets), cardiovascular drugs (Atorvastatin, Rosuvastatin Calcium tablets), diabetes drugs (Metformin HCl, Gliclazide tablets), post-operative pain injection, and FDA-approved Simvastatin tablets. Domestic and international sales.
• Consumer Health Products (健康产品) OTC and consumer health products including Lingzhi spore oil soft capsules, Jinchan egg white peptide beverage, Lianhua Qingyan antibacterial spray, and Lianhua Qingfei plant beverages, marketed under the Yiling Health sub-brand. Sold via e-commerce and retail channels.
• Wanbian Suanzaoren Oil Softgel (晚必安®以岭牌酸枣仁油软胶囊) Sleep aid softgel product under the Yiling brand Wanbian (晚必安) sub-brand, made from wild sour jujube kernel oil sourced from the Taihang Mountains, designed to improve deep sleep quality and promote restful sleep.

Quantifiable outcome

• Tongxinluo reduced no-reflow rate in acute MI PCI patients: ST-segment resolution 65.74% vs 45.95% in control group (P<0.01)
• +5 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered moderate and core.

• Gansu University of Chinese Medicine (甘肃中医药大学)moderateStrategic or Co-development Partner · 26 June 2026The Gansu University of Chinese Medicine delegation visited Yiling to explore industry-education integration and deepen industry-academia-research collaboration. Discussions focused on campus recruitment, building a long-term talent supply mechanism, joint research collaboration, and promoting Luo Bing theory education and Luo Bing discipline competitions. The partnership aims to strengthen talent cultivation and research output alignment with company needs.
• Kasem Bundit University (格乐大学) and Thailand Ministry of Public Health Traditional Medicine Research InstitutecoreStrategic or Co-development Partner · 4 June 2026A delegation from Thailand's Kasem Bundit University and the Thailand Ministry of Public Health's Traditional Medicine Research Institute visited Yiling Pharmaceutical's facilities including the academician workstation, TCM specimen museum, and bio-pharmaceutical industrial park. During the visit, Yiling donated the 'Compilation of Luo Bing Studies' (络学集成) to Kasem Bundit University, and both parties agreed to explore co-development of a TCM undergraduate program that would integrate Luo Bing theory into the university's curriculum. The partnership aims to expand Luo Bing academic education in Southeast Asian markets.
• Thailand Luo Bing Society (泰国络病学会)coreStrategic or Co-development Partner · 21 September 2024Established in September 2024, the Thailand Luo Bing Society is a key milestone in the international expansion of Luo Bing theory. Co-organized with the Thailand Chonburi Rajabhat University and supported by the World Federation of Acupuncture-Moxibustion Societies (世界中医药学会联合会络病专业委员会), the society promotes Luo Bing academic theory and TCM education in Southeast Asia. The society is part of the company's broader international Luo Bing academic network that also includes branches in the US, Canada, and Europe.
• World Federation of Acupuncture-Moxibustion Societies — Luo Bing Professional Committee (世界中医药学会联合会络病专业委员会)coreStrategic or Co-development Partner · 21 September 2024The World Federation of Acupuncture-Moxibustion Societies' Luo Bing Professional Committee co-organized the 20th International Luo Bing Academic Conference in Bangkok, Thailand in September 2024, bringing together experts from 13 countries and regions. This committee is the primary academic platform for promoting Luo Bing theory internationally and was instrumental in establishing the Thailand Luo Bing Society.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates covering chemical drugs, TCM, and healthcare distribution. Comparable as a large diversified Chinese pharma with both generic chemical drugs and TCM product lines, plus extensive hospital distribution.
• China Traditional Chinese Medicine Holdings (Sinopharm TCM): Largest TCM-focused company under Sinopharm, integrating TCM production, distribution, and clinical services. Comparable as a major TCM manufacturer with patented formulations and nationwide hospital/pharmacy distribution.

Direct peers

• Zhejiang Huahai Pharmaceutical: Chinese specialty pharma focused on cardiovascular and anti-HIV generic drugs with FDA-approved products. Comparable as a Chinese pharma with international FDA approvals and chemical drug manufacturing capabilities.
• Livzon Pharmaceutical Group: Chinese pharmaceutical company with biochem products, TCM preparations, and chemical APIs. Comparable as a mid-cap Chinese pharma combining proprietary TCM formulations with chemical drug manufacturing and broad therapeutic coverage.
• Yunnan Baiyao Group: Major Chinese TCM pharmaceutical company with branded proprietary products, integrated industrial chain, and broad consumer health portfolio. Directly comparable as another top-tier Chinese TCM innovator with patented formulations and broad consumer recognition.
• China Resources Sanjiu Medical & Pharmaceutical: Leading Chinese TCM pharmaceutical company under China Resources group, with OTC and prescription TCM products sold through hospital and pharmacy channels. Comparable in scale, branded TCM positioning, and China medical insurance coverage.
• Guangzhou Pharmaceutical Holdings (GPHL / Wanglaoji): Largest TCM enterprise in China and parent of Wanglaoji herbal tea brand. Comparable as a top-tier Chinese TCM company combining proprietary TCM formulations, generic chemical drugs, and consumer health products with hospital and retail distribution.
• Beijing Tongrentang: Historic Chinese TCM manufacturer with both proprietary TCM products and retail pharmacy distribution. Highly comparable as a top-10 Chinese TCM enterprise with patented formulations, hospital channel presence, and international expansion.
• Pien Tze Huang (Zhangzhou Pien Tze Huang Pharmaceutical): Historic Chinese TCM company with flagship proprietary formulation sold domestically and internationally. Comparable as a top-10 Chinese TCM manufacturer with patented proprietary products, hospital channel sales, and growing overseas presence.

Emerging players

• Hutchison China MediTech (Chi-Med / HUTCHMED): Innovative biopharmaceutical company developing TCM-derived and synthetic oncology drugs with international clinical programs. Comparable as a Chinese pharma with evidence-based clinical development targeting international regulatory approval.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/shijiazhuang-yiling-pharmaceutical-co-ltd

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shijiazhuang Yiling Pharmaceutical